Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hemoximer
- Development stage
- Phase 3
- Lead developer
- Curacyte
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Hemoximer (pyridoxalated hemoglobin-polyoxyethylene conjugate, or PHP) is a chemically-modified human hemoglobin developed as a nitric oxide (NO) scavenger. Originally conceived as a hemoglobin-based oxygen carrier (HBOC), it was repurposed to treat distributive shock, a condition characterized by excessive NO production leading to pathological vasodilation and hypotension. Developed by Apex Bioscience (a subsidiary of Curacyte AG), hemoximer consists of human hemoglobin modified with pyridoxal-5-phosphate and conjugated with polyoxyethylene to increase its molecular size and circulation time. Despite reaching Phase III clinical trials for catecholamine-resistant distributive shock, development was discontinued after interim analysis revealed increased mortality in patients receiving the drug compared to those on standard vasopressor therapy.
- Other names
- pyridoxalated hemoglobin-polyoxyethylene conjugatepyridoxalated hemoglobin polyoxyethylene
02
Targets
NO2- (Nitrite)
Beyond the preview
Go deeper on hemoximer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hemoximer.